Most phase II trials are also for new untested drugs. They often fail because of adverse events.
PPS is not a new drug. It's repurposed and been in use in humans for many decades.
Given those factors the odds change dramatically in PAR's favour.
Ann: Change of Director's Interest Notice, page-12
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.015(6.38%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $95.91K | 396.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 117676 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 36524 | 4 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |